SECTION I: ESTIMATION OF COSTS
| 1 | Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result. |
| … in terms of IPR protection | |
| There are no costs associated with IPR protection. | |
| …in terms of product development | |
| ‘myCerth’ software tool and the methodology for integrating administrative and financial procedures within a research organization have already been developed and thus there are no costs related to product development. The main costs are the personnel costs connected with the customization of the software tool depending on the needs and the procedures that each organization has. These costs are referred to the costs of mass production. | |
| …in terms of mass production | |
Costs in this category are related to the customization of the software tool depending on the needs and procedures that each client (research organization) has and consist of personnel costs, hardware/software, other equipment, travelling and other costs. All costs refer to a period of two-years:
Total: 365.000 € |
|
| … in terms of marketing | |
| Marketing costs refer to production of leaflets and travelling costs related to the promotion of the product. The total cost is estimated at 10.000 € for a period of two years. | |
| 2 | Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs | |||||
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | ||
| Fixed costs | 55.000 | 10.000 | 10.000 | 5.000 | 5.000 | |
| Personnel | 130.000 | 160.000 | 250.000 | 250.000 | 270.000 | |
| Other running costs | 10.000 | 15.000 | 15.000 | 15.000 | 15.000 | |
| Marketing costs | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 | |
| TOTAL EXPECTED COSTS | 200.000 | 190.000 | 280.000 | 275.000 | 295.000 | |
| Price per Unit | 70.000 | 70.000 | 70.000 | 70.000 | 70.000 | |
| Type of Unit | License | |||||
| Number of Units | 3 | 3 | 5 | 4 | 4 | |
| Subtotal | 210.000 | 210.000 | 350.000 | 280.000 | 280.000 | |
| Price per Unit | 20.000 | 20.000 | 20.000 | 20.000 | 20.000 | |
| Type of Unit | Technical support | |||||
| Number of Units | 3 | 6 | 11 | 15 | 19 | |
| Subtotal | 60.000 | 120.000 | 220.000 | 300.000 | 380.000 | |
| TOTAL Expected Revenues | 270.000 | 330.000 | 570.000 | 580.000 | 660.000 | |
| CASH FLOW REQUIRED (REVENUES-COSTS) | 70.000 | 140.000 | 290.000 | 305.000 | 365.000 | |
| TOTAL CAPITAL required for five years | 0 € | |||||
SECTION 2: QUALITATIVE FACTORS
| 3 | Dimension of identified target groups |
| In Greece operate 12 research centers, 20 research institutes connected with universities, 20 universities and 16 technological institutions. In the first five years we expect to implement ‘myCerth’ software tool in 8 research centers, 6 universities and 5 technical institutions. This part of the market consists of 40%. In the future, ‘myCerth’ tool can be promoted and implemented in foreign research organizations as well. | |
| 4 | Evaluation of financial Risks for R&D result |
| The main risk relates to the fact that the target group (universities and research centers) are public bodies and the implementation of software tools like ‘myCerth’ needs the (official or unofficial) approval of the government. Moreover, the economic situation of the Greek public sector is a restraining factor for investments. However, the need for transparency and high-principled management of financial resources may be the leading force for implementing high-quality IT systems. | |
SECTION 3: IDENTIFICATION OF FINANCING SOURCES
After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)
| 1. European FundingDefine relevance of the product with the following potential funding sources and comment |
| 1. … |
| 2. National Funding |
| 1. National Strategic Reference Framework 2007 – 2013 |
| 3. Private funding |
| 1. Own capital |
| 4. Other |
SECTION 3: FINAL EVALUATION
| It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)… |
|
Costas Kotoulas
